Approved Wire coverage, newest first. Market moves and thesis evidence remain separate.
Amazon shares jumped 15% while Apple lost roughly $475 billion in market value in a sharp divergence in mega-cap earnings reactions. The moves suggest investors are rewarding Amazon's growth trajectory ($716.9B revenue, +12.4% YoY) while punishing Apple despite still-strong margins (46.9% gross, 26.9% net) on slower top-line growth (+6.4% YoY).
Apple shares slumped following Tim Cook's final earnings report as CEO, while Microsoft rallied in the same big-tech reporting week. The divergence sets up a pairs question on which mega-cap has stronger near-term earnings momentum heading into the next stretch of the cycle.
Amazon's cloud unit posted sales growth that beat estimates, sending shares higher in reaction to the print. AWS acceleration reinforces the narrative that cloud capex spending by enterprises and AI workloads is translating into durable top-line growth for the hyperscalers.
Ferguson Enterprises shares jumped more than 8% after the plumbing and HVAC distributor was announced as a new addition to the S&P 500 index, displacing other candidates. Index inclusion typically forces passive funds tracking the S&P 500 to buy shares, creating a mechanical demand shock independent of fundamentals.
Apple beat on revenue and profit for the quarter, driven by stronger-than-expected iPhone sales, but Services revenue came in below targets. The mixed print puts focus on whether hardware strength can offset a slowing high-margin Services business heading into the next few quarters.
Ares Management's Q2 2026 slides show record $36B in quarterly fundraising, pushing AUM growth to 17% year-over-year. The scale of inflows underscores continued institutional appetite for private credit and alternatives, setting up a debate on whether fee-related earnings growth can keep pace with AUM expansion.
NatWest posted a 19.7% ROTE for H1 2026, the highest among UK peers, and raised full-year guidance in the accompanying slide deck. The print reinforces a multi-quarter run of improving capital returns and profitability that has made the stock one of the stronger re-rating stories in European banking.
Novo Nordisk shares fell 10% after a cardiovascular drug trial disappointed, undercutting the company's push to diversify beyond Wegovy and Ozempic. The setup now tests whether investors treat this as a one-off pipeline miss or as evidence Novo's ex-obesity growth story is structurally weaker than priced.
IES Holdings reported an EPS beat of $2.19 versus estimates with revenue also topping expectations, backed by FY revenue of $3.4B, up 16.9% YoY. The print shows strong profitability with 25.5% gross margin and 9.1% net margin, translating to $15.02 diluted EPS.
Grant Thornton agreed to buy publicly listed CBIZ for $5bn in an all-cash deal, marking the largest takeover in the accounting sector's recent history. The deal takes CBIZ private and sets up an arbitrage trade around deal-spread convergence into closing.
Meta shares fell as investors grew frustrated with the pace and scale of AI spending, prompting Mark Zuckerberg to announce plans to sell AI tools to other companies for the first time. The move signals a pivot toward monetizing AI infrastructure externally, but raises questions about whether it's enough to offset capex concerns.
Axos Financial beat Q4 FY2026 estimates and shares rose after hours on the print. The bank's FY2025 filings show $1.8B revenue (+9.7% YoY) and a 23.8% net margin, underscoring a consistently profitable niche-banking model heading into the reaction.
An FDA advisory committee voted 10-3 that IGNYTE study efficacy results for Replimune's RP1 in advanced melanoma are evaluable and clinically meaningful. The favorable panel outcome de-risks the path toward a PDUFA decision and reduces the odds of an outright rejection or request for another trial.
Dexcom's Q2 2026 slides showed a strong beat with a guidance raise and expanding margins, per Investing.com. The print reinforces the CGM growth narrative and sets up a test of whether the raise is enough to reaccelerate a stock that has lagged its own fundamentals in recent quarters.